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1 Abstract 
Chronic pain is a considerable health concern worldwide, effecting almost 30% of 
all European adults. Osteoarthritis (OA), a progressive pro-inflammatory condition, 
is one of the leading causes of chronic pain (effecting 13% of all those 50 years, 
globally) and is the most common cause of joint pain. The prevalence of non-
steroidal anti-inflammatory drug (NSAIDs) and analgesic use has been well studied 
and is abundant throughout the western world, with women being the greatest users 
and ibuprofen generally being the most reported. In the US, 65% of all OA patients 
are prescribed NSAIDs for pain management and form part of the current 
recommended strategy for OA clinical management. While some NSAIDs and 
analgesics are effective at improving pain and physical function, they come with 
significant and harmful side effects such as gastrointestinal complications, renal 
disturbances and severe cardiovascular events. Given these side-effects, any 
reduction in NSAID and analgesia use (and the resulting potentially harmful side 
effects) is of particular importance to OA public health. As such, a number of non-
pharmaceutical alternatives (bioactive nutraceuticals) have been developed that 
may reduce NSAID and analgesia use while maintaining pain reduction and 
improvements in physical function. This chapter will discuss select nutraceuticals 
that are not currently in mainstream use but may have the potential to aid in the 
treatment of OA. 
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2 Introduction 
2.1 Chronic Pain 
Pain occurs in all demographics, with a higher prevalence in some clusters (such as 
the elderly) and can be either acute or chronic [1, 2]. Chronic pain is a complex 
interplay between biology and psychology, where the intensity/magnitude differs 
depending on personal, sensory, emotional experience and persists more than 3 
months beyond “normal” healing time [3, 4]. This type of pain affects more than 1.5 
billion people worldwide [5] and has an estimated prevalence ranging between 17-
27% [6-9]. Chronic pain represents a significant financial burden that exceeds €300 
trillion (approximately 1.5%-3% of the gross domestic product across the European 
Union) and up to $635 billion in the United States [10, 11]. According to the 
International Association for the Study of Pain (IASP), the main overarching 
categories of chronic pain are primary (such as fibromyalgia) and secondary pain 
(the focus of this chapter). Secondary chronic pain is further divided into six distinct 
categories: cancer-related pain, postsurgical or posttraumatic pain, secondary 
headache/orofacial pain, secondary visceral pain, and secondary musculoskeletal 
pain [12, 13]. 
 
Most chronic pain begins with the occurrence of an acute injury event resulting in 
pain that if left untreated can develop chronically pathological and will increase the 
risk of future deleterious health issues such as sleep deficiency, delayed wound 
healing, immune dysfunction, cardiovascular problems (related to the stress 
response) and respiratory problems [such as pneumonia; 14, 15]. Furthermore, 
persistent, unrelieved pain can negatively impact quality of life, daily functioning, 
sleep quality, work productivity and is associated with a substantial personal 
economic burden [16]. 
 
Pathologic pain is associated with multiple maladaptations in the nervous, 
endocrine, and immune systems [17-19] that often presents at multiple sites [20] 
and can be classified into nociceptive (somatic and visceral), neuropathic, 
nociplastic, or mixed [21]. Nociplastic describes pain of unknown origin that arises 
from altered nociception, despite no clear evidence of actual or threatened tissue 
damage that causes activation of peripheral nociceptors, evidence of disease or 
lesion of the somatosensory system causing the pain, such as early (pre structural 
damage) osteoarthritis [21]. Similarly, recent suggestions propose that generalised 
chronic pain is an expression of maladaptive plasticity within the nociceptive system 
[22, 23] and relevant to the present chapter as osteoarthritic pain is generally 
accepted to be mainly of nociceptive origin [24]. 
 
2.2 Mechanisms of nociceptive pain 
Most painful conditions initially involve the activation of dorsal root ganglion 
(DRG) neurons, which give rise to high threshold Aδ- and C-fibres (nociceptors) that 
innervate peripheral tissues [skin, bone, joints, viscera; 25]. Primary afferent 
neurons transduce painful stimuli action potentials through to the spinal cord (to 
ascending spinal neurons). Transmission of input from nociceptors, through the 
spinal column and to the central nerves system is mediated by monosynaptic 
contacts and/or through interneurons [19, 26]. In the spinal cord, neurotransmitter 
inhibition is mediated by the release of endogenous opioids [such as met-
enkephalins and endorphins; 27] or gamma-aminobutyric acid (GABA) which 
activate presynaptic opioid and/or GABA receptors on central nociceptor terminals 
to reduce excitatory transmitter release (Figure 1). The central integration of signals 
from excitatory and inhibitory neurotransmitters from cognitive, emotional, and 
environmental factors results in the perception of “pain”. When the intricate balance 
between biological (neuronal), psychological (i.e. memory, distraction etc.) and 
social (i.e. attention, reward etc.) factors becomes disturbed, chronic pain develops 
[18]. 
 
Pain that is induced by an acute injury, initially localized, relatively proportional to 
the degree of tissue damage and typically increases with movement is referred to as 
“nociceptive pain.” Specifically, as immune surveillance cells recognize the danger 
signals unmasked by tissue injury, the innate immune system initiates an 
inflammatory response to remove cellular debris and begins the healing process. 
Activated endothelial cells, stromal cells, and infiltrating immune cells release 
vasoactive and inflammatory mediators, including histamine, bradykinin, 
substance P, serotonin, nitric oxide, cytokines, chemokines, and prostaglandins, 
which amplify signal transduction in the peripheral terminals of nociceptors [26, 
28]. These inflammatory mediators augment the responsiveness of nociceptors by 
increasing expression of pain-sensing ion channels and promoting release of 
pronociceptive mediators [autosensitization; 29]. This peripheral inflammation 
caused by local injury and continuous inputs from sensitized nociceptors promote 
‘central sensitization’, a process that alters pain processing in the spinal dorsal horn, 
and in subcortical and cortical regions of the brain [30, 31]. Noxious signals 
associated with the injury are detected by peripheral nociceptor terminals of 
primary afferent neurons, transmitted via the spinal cord to the brain, processed 
and interpreted as highly unpleasant pain experiences [32]. Nociceptor terminals 
express molecules, such as transient receptor potential ion channels (TRP), voltage-
gated sodium channels (Nav), voltage-gated calcium channels (VGCC), or acid-
sensing ion channels (ASICs), which respond to heat, cold, acids, or mechanical 
stress and transduce them into action potentials [26]. The signal is then transmitted 
through peripheral axons to the cell bodies of the primary neurons, located in the 
dorsal root ganglia. Unmyelinated C-fibres and myelinated Aδ-fibres transmit 
noxious stimuli, whereas thinly myelinated Aδ-fibres transmit innocuous 
mechanical stimuli, such as touch. The central axons of the primary neurons enter 
the spinal cord through the dorsal horn and synapse with secondary somatosensory 
neurons and, to some extent, with motor neurons to form withdrawal reflex circuits. 
Signal propagation to the secondary neurons is subject to modulation by descending 
tracts from the brainstem and by interneurons in the dorsal horn. The signal is then 
transmitted to the thalamus, from where tertiary afferent neurons are projected to 
multiple areas of the cortex involved in pain processing [33]. 
 
2.3 Mechanisms of neuropathic pain 
Neuropathic pain (NP) is defined as “pain caused by a lesion or disease of the 
somatosensory nervous system” [34]. Chronic neuropathic pain is caused by 
damage to nerve fibres in the nervous system that then respond by misappropriating 
sensory inputs leading to spontaneous painful sensation, through multiple 
mechanisms in the nervous system and its associated modulators. Peripheral nerve 
damage can result in chronic neuropathic pain through multiple routes [35] via 
peripheral pain-processing unmyelinated C-fibres and thinly-myelinated ad-libbers 
because of metabolic damage, toxins, medications, cytokines, and inflammation 
[36]. This can result in morphological and chemical changes such as fibre density 
and neuronal hyperexcitability [30, 37-40]. Throughout the axon, trauma, 
compression, hypoxia, inflammation and chemical damage lead to fibre 
degeneration and alterations in gene expression [41], resulting in ectopic firing, 
faulty signal transmission [42], detrimental physiological alterations [43-45] and 
peripheral second-order targets [46-48]. This results in negative impacts on 
nociceptive pathways causing them to become sensitized [49], leading to 
maladaptive central sensitization [50] and increased responsiveness of nociceptive 
neurons in the central nervous system to their normal or subthreshold afferent input 
[51]. At the molecular level, these damaged processes disrupt second-order 
neuronal transduction, through alterations in receptor expression, calcium 
permeability, synapse location and the release of pain-promoting mediators [52-
55]. The precise molecular targets of neuropathic pain stem from multiple 
mechanisms of peripheral nerve fibre excitation and sensitization leading to 
sustained electrochemical signalling leading to the neuropathic pain stimulus [56, 
57]. 
 
2.4 Pharmaceutical treatment of chronic pain  
Both acute and chronic pain are, in general, treated with a wide group of 
pharmaceutical medications known as “analgesics.” The most frequently used are 
opioids, nonsteroidal anti-inflammatory drugs (NSAIDs) and paracetamol also 
referred to as acetaminophen or N-acetyl-p-aminophenol [58]. 
 
2.4.1 Opioids 
Opioid drugs (e.g. morphine, codeine, methadone, fentanyl and their derivatives) 
are the most widely used analgesic medications globally, so much so that an 
estimated 26.8 million people were living with ‘opioid use disorder’ globally in 2016, 
resulting in >100,000 opioid overdose deaths annually [59]. Opioids are a group of 
pharmaceutical formulations that interact with endogenous opioid receptors to 
distort neurotransmitter singling pathways through localized peripheral sensory 
neurons [60, 61] with the goal to reducing pain sensation. Opioid receptors are a 
large superfamily of seven-transmembrane G protein-coupled receptors and are 
classified as µ (µ1, µ2, µ3), δ (δ1, δ2), k (k1, k2, k3) and ORL1 [62, 63], of which 
almost all opioid drugs in use today interact with µ receptors. These receptors are 
inhibitory and prevent the presynaptic release of a number of neurotransmitters to 
inhibit the release of glutamate, calcitonin gene related protein (CGRP), and 
substance P. This is an important action considering the established roles of these 
molecules in pain signalling and nociceptive transmission [Figure 1; 64]. For 
example, morphine, extracted from opium, is by far the most commonly known 
opioid [59], which is thought to be in use since the third century B.C. [22], but 
identified at the molecular level to have a high binding affinity to sites in the 
intestine and brain [65]. These receptors mediate an inhibitory signal of neural 
transmission induced by opioid drugs to produce an analgesic action (Figure 1). Pain 
stimuli are detected by nociceptors at the spinal cord dorsal horn [66] where they 
act on the substantia gelatinosa, (inhibitory interneurons rich with opioid receptors) 
and are activated by the antinociceptive descending system, to control the 
transmission of painful stimuli from primary nerve fibres to spino-thalamic neurons 
[22]. Opioid receptors have an intricate relationship with inflammatory status. Early 
studies showed that the systemic or local application of receptor agonists elicited 
greater analgesic effects in inflamed compared to non-inflamed tissue [reviewed in; 
67]. Furthermore, opioid receptor trafficking (movement within the neuron) is 
augmented, expression on DRG membranes is enhanced [68, 69] and axonal 
transport stimulated by cytokines and nerve growth factor that are produced within 
inflamed tissues [70, 71]. This enhanced/altered state resulted in increased 
antinociceptive function of opioid receptors on peripheral nerves [60, 72]. 
 
The major limiting factors of opioid therapy are the variety of side effects such as 
constipation, vomiting, myosis, cough reflex suppression, modulation of the 
immune system and one of the most dangerous, respiratory rhythm and respiratory 
depression [73, 74]. Interestingly, studies have shown their long-term use in chronic 
non-malignant (e.g. musculoskeletal) pain has not been proven effective [75], 
rather, abuse of prescription opioids have reached epidemic proportions leading to 
addiction, overdoses and increased death rates [76-78]. Importantly, these side 
effects may be drug specific and affect immune function differently [79, 80]. 
Nonetheless, chronic use of opioid medication can cause cellular adaptions that lead 
to modulation of cellular growth, inflammation, wound healing [81, 82] For a more 
detailed overview of the potential side effects and opioid tolerance see, [83-86]. 
 
Regardless of the potential impact that opioid agonists could have on pain relief, 
meta-analyses show no improvement in clinically significant pain reduction scores, 
and epidemiologic data suggest that quality of life and functional capacity are only 
minimally changed [75, 78]. Nonetheless, more data is required from larger studies 
(specifically in OA), however the aforementioned adverse effects and lack of 
analgesic efficacy has led to significant dropout rates in long-term studies [75, 78, 
87-89]. 
 
2.4.2 Non-steroidal anti-inflammatory drugs (NSAIDs) 
NSAIDs (particular enzyme inhibiters) are among most widely used medications 
globally [90, 91] because of the lower potential for addiction [as shown by the US 
opioid epidemic; 92], robust efficacy, and long history of clinical use [93]. 
 
The prevalence of ‘non-aspirin’ NSAID use has been well studied and is dynamic 
across age, body mass index and geographical ancestry, ranging between ~15-45%, 
women being the greatest users and ibuprofen generally being the most reported 
[94-96]. Short-term use of NSAIDs is particularly prevalent (perhaps 50–80% per 
year) in athletes and soldiers [individuals that may be at risk for acute and chronic 
musculoskeletal injuries; 97, 98, 99]. Extended periods of NSAID treatment (e.g., 
more than 3 times per week for more than 3 months per year) have been reported 
by 10% of adults in the United States [100] a rate that can be expected to increase 
with age [101]. 
 
NSAIDs act primarily by mediating peripheral pain sensitization driven by 
inflammatory stimuli, such as acute or sport injuries, (osteo)arthritis etc. and are 
less effective in treating pain due to nerve damage (neuropathic pain). At the point 
of inflammatory pain, initiated by nociceptive stimuli, NSAIDs augment the 
experienced nociceptive excitability [peripheral and central sensitization; 102]. 
NSAIDs work differently to opioids in that they do not block central pathways of 
nociception, but inhibit the formation of prostanoids via competitive inhibition of 
arachidonic acid binding to cyclooxygenase enzyme (COX) isoform active sites [103] 
which sensitise nociceptive pain. There are two cyclooxygenase isoforms that are the 
targets of NSAIDs; COX-1 that are expressed in most tissues (including the 
endothelium, monocytes, gastrointestinal epithelial cells, and platelets) and 
controls the basal production of prostanoids (Figure 1) and COX-2 that are not 
regularly expressed in most tissues but are upregulated in response to and during 
the inflammatory process (in tissues such as vascular endothelium, rheumatoid 
synovial endothelial cells, monocytes, and macrophages) through the actions of 
various inflammatory mediators such as bacterial endotoxins, tumour necrosis 
factor-alpha and interleukins [104]. The increase in COX-2 protein levels are the 
primary driving force for enhanced production of prostanoids at inflammatory sites 
[105, 106]. The resulting COX-2 products, particularly prostaglandin (PG) E2, 
potentiate this response, where PGE2 and prostacyclin (PGI2), produced during 
local inflammation, augment pain signalling by peripheral and central neurons [15]. 
PGE2 and PGI2 increase the sensitivity of pain receptors (or nociceptors) in the 
periphery and enhance the activity of various pain mediators [104, 107]. This 
mechanism propagates via brain derived PGE2 traveling through the blood–brain 
barrier, via venules, during systemic inflammation and lessens the inhibition of 
neurons in the hypothalamus [108]. Drugs that inhibit both COX isoforms with 
comparable potency (i.e. nonselective NSAIDs such as ibuprofen and ketoprofen) 
tend to preferentially activate the COX-1 pathway, while drugs with intermediate or 
selective target COX-2 inhibition (such as nimesulide, meloxicam, diclofenac, 
celecoxib, rofecoxib, etoricoxib, lumiracoxib etc.) have lesser potential for COX-1 
activation [109]. This pathway selectivity is of significant importance as both COX 
isoform elicit different potentially harmful adverse effects. 
 
In a recent meta-analysis (n=220,000 patients) of placebo-controlled trials, 
NSAIDs (coxibs, diclofenac, ibuprofen, and naproxen, predominantly COX-1 
inhibiters) significantly increased the risk of upper gastrointestinal complications 
[eg, ulcer perforations, bleeding, obstructions; 110]. The authors also showed an 
increased risk of major vascular and major coronary events with high doses of coxibs 
and diclofenac while ibuprofen was associated with an increase in major coronary 
(but not vascular) events comparable with that of coxibs and diclofenac 
[predominantly COX-2 inhibiters; 110]. These data are corroborated with findings 
from meta-analysis of observational studies showing low risk of upper 
gastrointestinal complications (aceclofenac, celecoxib, and ibuprofen 
predominantly COX-2 inhibiters), intermediate risk (diclofenac, meloxicam, and 
ketoprofen etc.) and high risk (tenoxicam, naproxen, indomethacin, diflunisal, 
piroxicam, ketorolac, and azapropazone predominantly COX - inhibiters) 
depending on the NSAID, likely in a dose dependent fashion [111]. Similarly, total 
daily oral diclofenac had a linear dose dependent relationship cardiovascular event 
risk [112]. These dose dependencies are likely a product of the relative effectiveness 
on either COX-1 or COX-2 inhibition [113-116]. As both (non-inhabited) COX-1 and 
COX-2 produce cytoprotective prostanoids, inhibition of both COX isozymes 
(induced by NSAIDs) suppress these prostanoids and promotes damage to the 
gastrointestinal tract and cardiovascular tissues [109, 117]. Based on these and other 
safety findings, the American Heart Association recommends patients take the 
lowest effective dose of NSAIDs for the shortest duration of time [118].  
 
2.4.3 Paracetamol (acetaminophen, N-acetyl-p-aminophenol; APAP) 
APAP are likely to be the most commonly used pharmaceutical worldwide [119, 
120], are expected to reach a global market value of USD 999.4 million in 2020 [121] 
and is included in the 21st World Health Organization Model List of Essential 
Medicines as updated in March 2017 [122]. However, recently there have been 
debates from the National Institute for Health and Care Excellence, about the 
relevance APAP for some conditions [123]. The efficacy of paracetamol to treat 
chronic pain has been questioned with systematic reviews showing limited 
(sometimes null) effects on chronic pain in some conditions [120, 124, 125]. 
Nonetheless, APAP can be beneficial for acute pain, [126-128], similar to NSAIDs 
and opioids [129-131]. The precise mechanism of action remains unknown, however 
this is most likely due to the interwoven interactions that APAP have in multiple 
pain pathways. Our current knowledge suggests that APAPs are metabolised by the 
liver into p-aminophenol, then bound with arachidonic acid, primarily in the brain, 
to form AM404 (N- (4-hydroxyphenyl)-5Z,8Z,11Z,14Z-eicosatetraenamide) through 
fatty acid amide hydrolase (FAAH) activity [132-134]. Like NSAIDs, APAP are 
analgesic and antipyretic, however APAP lacks peripheral anti-inflammatory 
properties, therefore act through the central nervous system and not peripheral 
tissues [135]. Current evidence suggests that there are four metabolic systems that 
interact to elicit the analgesic and antipyretic properties of APAP, the Eicosanoid, 
Opioidergic, Seretogentic and Endocannabinoid systems [136]. 
 
Briefly, like NSIADs APAP can inhibit central cyclo-oxygenases (COX-1, COX-2) 
including a proposed third isoform COX-3 [137-142]. Although the results are 
controversial [143] it is thought that they are involved in prostaglandin (PGs) 
production thus the analgesic mechanism of action. Furthermore, APAP are more 
effective in environments with low peroxide tone and low arachidonic acid levels, 
such as in the central nerves system, mainly through local depletion of glutathione 
leading to decreased production of PGE2 [139]. Considering the antinociceptive 
effects of APAP, one of the main brain derived metabolites AM404 (N-arachidonoyl-
phenolamine) is decrease in the presence of opioid receptor antagonist. AM404 
inhibits the nociceptive activity of particular APAPs in part by modulating many 
neurotransmitters, including 5-HT, glutamate, and γ-aminobutyric acid [143-145]. 
Although the precise receptors have not been identified [146-149], serotonin 
antagonists block the analgesic effect of APAP through mainly indirect non-binding 
mechanisms [146, 150]. One possible interaction with the serotonergic pathway 
maybe though altering CNS monoamine neuron types in the brain that contain a 
major receptor for PGE2 (EP3 receptor [139]. Further to the above, AM404 can 
inhibit anandamide [151], with stimulation of (canobinoide 1) CB1 receptor activity 
(without binding) via FAAH [133], suggesting a reliance of APAP antinociceptive 
activity on interaction with the endocannabinoid system [134, 152]. Interestingly, 
AM404 is not identifiable in the blood after APAP administration [133] which might 
explain, to some degree, the absence of peripheral anti-inflammatory action [134]. 
This could help to explain why APAP may not have significant clinical effect on 
conditions such as osteoarthritis [further details below; 153, 154]. A recent study 
confirmed that APAPs act mainly on central analgesic pathways, showing that APAP 
modifies the activity and connectivity of analgesia via FAAH, activating a signalling 
cascade involving TRPV1 channels, mGlu5 receptors, PLC, DAGL and CB1 
receptors, associated with the release of glutamate and GABA – through the 
endocannabinoid systems [155]. Though the molecular mechanisms that provide 
analgesia are beginning to come to light, there is also potential substantial 
detrimental side effects of APAPs. 
 
APAPs are generally considered safe if administered at appropriate doses for short 
periods [156]. However, they remain one of the leading causes of liver disease in 
high-income countries [157, 158] which has led to legislative restrictions in many 
countries [see, 159]. It is well accepted that APAPs cause liver injury, hepatotoxicity, 
mitochondrial toxicity [160, 161] and that this toxicity can be effected by 
interindividual variation [162]. Nonetheless, consuming APAP can increase the 
risks of hospitalisation for perforation, peptic ulceration and bleeding [163], relative 
rates of adverse cardiovascular events such as myocardial infarction, stroke, 
coronary heart disease and upper gastrointestinal disease such as gastroduodenal 
ulcers and haemorrhages [164], often in a dose response manor. However, 
observational studies show a favourable side effect profile for APAPs compared with 
NSAIDs used in older people with chronic pain conditions [165]. Data from the most 
recent meta-analysis shows that APAPs are nearly four times more likely to have 
abnormal results on liver function tests than placebo [166]. 
3 Osteoarthritis  
Osteoarthritis (OA) is a complex musculoskeletal condition that effects people of all 
ages but particularly those over 55 years [167-171]. According to the Osteoarthritis 
Research Society International (OARSI) OA can be defined as; 
 
“…a disorder involving movable joints characterized by cell stress and extracellular 
matrix degradation initiated by micro- and macro-injury that activates 
maladaptive repair responses including pro-inflammatory pathways of innate 
immunity. The disease manifests first as a molecular derangement (abnormal joint 
tissue metabolism) followed by anatomic, and/or physiologic derangements 
(characterized by cartilage degradation, bone remodelling, osteophyte formation, 
joint inflammation and loss of normal joint function), that can culminate in 
illness” [172] 
 
OA is a pro-inflammatory branch of rheumatic disease that effects synovial joints 
progressively and is caused by the failure of  joint tissues to repair following damage. 
This damage may have been caused by stresses due to an abnormality in the 
articular cartilage, subchondral bone, ligaments, menisci, periarticular muscles, 
peripheral nerves or synovium [173, 174]. While cartilage degradation is the 
traditionally structural trademark of OA, it is generally considered a whole joint 
disease with many other morphological features [175-178]. For example, an 
osteoarthritic joint may exhibit sclerosis in the subchondral bone, osteophytes [179], 
local inflammation such as synovitis [177, 178, 180, 181] and bone marrow lesions 
[182]. Failure of normal biological repair processes that leads to breakdown of 
cartilage and bone [183] is characterised by symptoms of pain, stiffness, functional 
disability [184] that can lead to negative impacts on fatigue, mood, sleep, overall 
quality of life [185, 186]. 
 
OA confers a number of modifiable and non-modifiable risk factors [174, 187]. Non-
modifiable risk factors include previous joint injury [188, 189], malalignment and 
other mechanical factors [175, 176, 190-193], age [189], sex [194], ethnicity [195] 
and genetic predisposition [196-198]. Modifiable risk factors include obesity [181, 
189, 199-202], metabolic syndrome [181, 203-206], in particular diabetes mellitus 
[207-209] and habitual diet [187, 210]. 
 
The condition is one of the most common causes of chronic pain and the most 
common cause of joint pain [211] with conservative estimates suggesting that there 
are approximately 500 million suffers worldwide [167, 212]. OA affects ~13% of all 
over 50’s [~7% in all ages; 213] and has no cure [214-218] while being the 11th 
highest contributor to years lived with disability [159]. 
 
3.1 Pain and osteoarthritis 
Chronic inflammatory-associated pain can have multiple mechanisms [219-223] 
and can stem from mechanical stress or central sensitization either concurrently 
and/or vary in their influences over time [224]. Pain derived from OA can generally 
be characterised into two common clinical forms of pain, intermittent but 
severe/intense and persistent pain or aching [225]. These pain experiences can 
come from neuropathic and nociceptive process, as discussed above. The prevalence 
of neuropathic pain features at the knee in OA patients ranges from 19% to 29% 
[221, 226, 227]. However, recent studies of peripheral and central nerve 
sensitization [228], as well as nerve ending damage and regrowth [229, 230] have 
shown that neuropathic pain contributes substantially to the condition. This central 
sensitization is prominent in those that experience a high level of pain that is not 
proportional to radiographic evidence of structural damage [219] and contributes 
more to the pain experienced in women with symptomatic OA, compared to men 
[231]. Generally, a higher degree of central sensitization or neuropathic pain is 
associated with high pain intensity and a greater chance of developing chronic pain 
following joint replacement [232, 233]. The remaining 70-80% of knee OA pain 
appears to be nociceptive in nature, thus OA can be described as a chronic mild to 
moderate nociceptive dominant pain condition [24, 234]  and should be considered 
as such with regards to initial treatment [24]. 
 
The diversity of pathophysiological maladaptation in OA effected joints and the low 
associations of these changes with pain, suggests doubt over the link between joint 
structural condition and the experience of pain. This is evident from the poor 
relationship between radiographic images and reported pain. A recent systematic 
review showed that the prevalence of knee pain in patients with radiographic knee 
OA ranged from 15% to 81% [235]. However, some studies reported associations 
between the structural damage of the joint (cartilage and bone) and pain [236] but 
at higher levels of X-ray derived pathology [Kellgren/Lawrence grade; 237]. 
Nonetheless, pain may still indicate a level of disease activity. In a number of studies 
looking more specifically at joint morphological characterises, OA pain has been 
associated with the rate of medial cartilage loss [also after adjustment for 
radiographic OA stage; 238], osteophytes [239], more erosive OA compared to non-
erosive OA [240] and changes of bone marrow lesions and synovitis [182]. These 
data show the complexity of the disease-pain nexus and suggests that the disease 
should, in the first instance (i.e. mild OA), be treated generally with lifestyle and 
nutritional intervention rather that pharmaceuticals that target specific 
pathological pathways (figure 1). [241]. Regardless, pharmaceutical therapies 
remain the main treatment for such conditions [242]. 
 
3.2 Pharmaceutical analgesics in Osteoarthritis 
OA is a progressive condition with no cure where opioids, acetaminophen and non-
steroidal anti-inflammatory drugs (NSAID) are the traditional, non-lifestyle, 
approach for early management. However, as eluded to earlier, these 
pharmaceutical treatments are often accompanied with significant side effects. For 
example, NSAIDs are the traditional approach for early clinical management of 
mild-to-moderate OA [241] and in the US 65% of all OA patients are prescribed 
NSAID for pain management - this is the current recommended strategy for OA 
clinical management by the leading authorities [243]. While some NSAIDs are 
effective at improving pain and physical function, they come with significant and 
potentially harmful side effects such as gastrointestinal complications, renal 
disturbances and severe cardiovascular events [244]. Although some of these risks 
may be reduced using topical administration such as Diclofenac gel/cream [245, 
246]. Two recent large-scale studies have shown that, depending on the particular 
medication, the risk of hospital admissions (due to heart failure) can be nearly two 
times greater [Ketorolac; 247] in OA/rheumatoid arthritis (n=24,081). ibuprofen 
(generally speaking, the most used NSAID) had the highest rates of NSAID toxicity 
[248]. 
 
Approximately 34% of OA patients use Paracetamol [249], in isolation or in 
combination with NSAIDs. In fact, the effectiveness of Paracetamol to improve pain 
management has recently been called into question [124], as it has been shown to 
be ineffective for treating OA pain [125, 250] and may have similar side effects as 
ibuprofen [251] particularly when consumed at higher doses [164]. Specifically, in 
knee or hip OA, a recent Cochrane review concluded that Paracetamol provides no 
clinically important improvements in pain in the immediate and short term [up to 
12 weeks; 16]. In addition, a recent network meta-analysis (56 randomised 
controlled trials, 22 128 participants) suggests that paracetamol was least effective 
for the treatment of knee and or hip OA compared with celecoxib (NSAID) or the 
combination of glucosamine and chondroitin [117] – confirming other reports [252]. 
In contrast, some authors have concluded that paracetamol had similar efficacy to 
NSAIDs for the treatment of OA [253]. It is also important to remember that overuse 
of APAPs can cause liver injury, hepatotoxicity, mitochondrial toxicity [160, 161] 
which is relevant to a chronic condition with no known cure. These data led to 
confusion in earlier guidelines that consistently recommended the prescription of 
paracetamol (acetaminophen) as the first line analgesic for these conditions.[90, 91, 
241, 254, 255]. However, the data are now relatively clear that there is little clinically 
meaningful effect of Paracetamol on OA pain [153, 154]. 
 
The potential negative effects such as addiction and the physiological side effects of 
opioid use are well documented, as discussed above, however they remain highly 
prescribed for OA and are expected to triple in the coming years [256, 257]. More 
than half of those prescribed opioids in the first year of OA have been shown to be 
inappropriately dispensed [257]. The prevalence of opioid use for OA ranges from 
8-26% and in Australia, the use for knee/hip OA has been described “alarmingly 
high” [257]. A number of systematic reviews and meta-analysis have been 
performed in recent years and have unanimously shown that the tolerability is low, 
efficacy for pain relief in OA is not clinically relevant and the potential harms are 
high [258-260]. Despite calls for guidelines to be changes on the use of opioids and 
the above-mentioned pharmaceuticals, their use is increasing (likely with the 
prevalence of the disease) and by proxy the negative consequences will rise in 
tandem. Therefore, non-pharmaceutical food-based alternatives (termed 
nutraceuticals;) have been developed and are beginning to be recommended as early 
intervention treatment [261-263] to improve OA symptoms including pain [241, 
264-266]. 
 
4 Nutraceutical alternatives and reduction in pharmacological 
analgesics in osteoarthritis 
Given the possible side-effects of pharmaceutical treatments, any reduction in their 
use is of particular importance to OA public health. As such, a number of non-
pharmaceutical alternatives have been developed that may reduce the use/required 
dose of pharmaceuticals while maintaining or improving the impacts on OA pain 
and physical function. The majority of these alternatives are termed “nutraceuticals” 
(a portmanteau of the words “nutrition” and “pharmaceutical”), coined in 1989 by 
Dr Stephen DeFelice [267], founder and chairman of the Foundation for Innovation 
in Medicine. 
 
While it is unlikely that Hippocrates (traditionally regarded as the father of modern 
medicine; died in 375 BCE) actually said: “Let food be your medicine and medicine 
your food” [268], this is often cited in the context of nutraceuticals. A more apt and 
legitimate quote defines the position of nutraceuticals in health and disease as 
“beyond diet, before drug”, coined by Ettore Novellino in 2012 [269]. 
 
There is currently no universally accepted definition of a nutraceutical [270], with 
the main confusion being the differences between nutraceuticals and functional 
foods, and the lack of regulatory definition between them [Table 1; 270, 271, 272, 
273]. In fact, current European regulations do not distinguish between 
nutraceuticals and food supplements (see the EC Regulation n. 1924/2006 of the 
European Parliament and Council, recently updated by the UE regulation 
2015/2283), therefore neither does the European Food Safety Authority [274, 275]. 
However, a number of proposed definitions exist (Table 1) and from these 
definitions, for the purposes of this chapter, a nutraceutical will be defined as; a 
naturally derived biological substance, not synthetically created, that preserve their 
original active properties without chemical manipulation, can enhance health in 
dosages that exceed those that could be obtained from normal food digestion and 




267; coined in 
1989] 
“A nutraceutical is any substance that is a food or part of a food 
and provides medical or health benefits, including the 
prevention and treatment of disease.” 
[Zeisel, 271] “……as those diet supplements that deliver a concentrated form 
of a presumed bioactive agent from a food, presented in a non-
food matric, and used to enhance health in dosages that exceed 






“a dietary supplement, food or medical food that has a benefit, 
which prevents or reduces the risk of a disease or health 
condition, including the management of a disease or health 
condition or the improvement of health; and is safe for human 
consumption in the quantity, and with the frequency required 






“are nutritional products that provide health and medical 
benefits, including the prevention and treatment of disease. In 
contrast to pharmaceuticals however, these are not synthetic 
substances or chemical compounds formulated for specific 
indications. These are products that contain nutrients (partly in 
concentrated form) and mostly are assigned to the category of 
food. Dietary supplements are a typical example for 
nutraceuticals, but also dietetic and functional foods may be 
counted among these products.” 
[Health 
Canada, 278] 
“A nutraceutical is a product isolated or purified from foods that 
is generally sold in medicinal forms not usually associated with 
food. A nutraceutical is demonstrated to have a physiological 
benefit or provide protection against chronic disease” 
[Corzo et al., 
279] 
“Nutraceuticals are biological substances extracted from 
natural sources by non-denaturing processes to preserve their 
original properties without any chemical manipulation.” 
 
Table 1. Currently used definitions to describe nutraceuticals. 
 
As such the following sections will discuss those nutraceuticals that are currently 
not in mainstream use but may have the potential to aid in treatment of OA (i.e. the 
well discussed Glucosamine and Chondroitin will not feature in this article) but are 
in regular use worldwide [280]. The identified nutraceuticals that have been directly 
compared to NSAID/analgesics with OA can be divided into three categories, 
defined by their origin, and are presented in Table 2;  
1) Terrestrial Botanicals, compounds derived from ‘land’ plant sources 
(avocado/soybean, pine bark extract and turmeric/curcumin) 
2) Marine Botanicals compounds derived from ‘marine’ plant sources 
(Lithothamnion species) 











300 mg or 600 mg ASU for 3 months 
 
↓ NSAIDs and analgesics use by 50% vs placebo 




Piascledine/ASU (300 mg daily) for 6 months 
 
 
↓ Participants using analgesics and NSAIDs (from 58.8% to 24.9%) 
↓ Median pain (by ~50%) and pain intensity, pain at rest (by 100%) and pain during 
walking (by ~60%) 




Avocado/soybean mixture, 300 mg daily orally versus 
celecoxib,200 mg/day orally for 8 weeks 
↓ Cartilage oligomeric matrix protein (COMP) in both groups (by ~37%, 




Phytalgic (fish-oil, vitamin E, Urtica dioica) 3 capsules 
daily for 12 weeks 
↓ NSAIDs use vs the placebo (by ~60%) 
↓ Analgesic use vs the placebo (BY ~40%) 




600 mg of BioLex(R)-GLM extract daily or placebo for 
12 weeks 
↓ Paracetamol use (by ~ 30% post-trial) vs placebo 
↓ Stiffness (by ~19%) vs placebo, no difference pain 
[285] 
Pine bark extract Pycnogenol (pine bark extract) 100 mg for 3 months ↓ Use of drugs (by ~57%) vs placebo 
↓ Gastrointestinal complications (by ~60%) vs placebo 
↓ WOMAC score (by ~40%) vs placebo 
↑ Walking distance (by ~34%), compared to no improvement in placebo 
[286] 
Turmeric Turmeric extracts (2 g extracts/day) or ibuprofen 
(800 mg) for 0, 2, 4 and 6 weeks 
↓ Pain on walking stairs vs ibuprofen (however, ibuprofen was greater at baseline 
thus throughout) 
No difference in pain on level walking, 100 m walking time or stair climb 
[287] 
Turmeric Turmeric extracts (1500 mg extracts/day) or 
ibuprofen (1200 mg/day) for 4 weeks 
↓ WOMAC score, pain and function compared to baseline scores at all time points, 
and was non-inferior to ibuprofen. 
↓ Rate of abdominal pain/distention vs ibuprofen (by ~60%) 
[288] 
Curcumin BCM-95® Curcumin: 500 mg/capsule twice daily, 
Curcumin 500 mg + diclofenac sodium 50 mg/capsule 
twice daily, diclofenac 50 mg/ capsule twice daily, all 
for 8 weeks 
↓ Disease Activity Score (by ~45%), CRP (by ~52%), American College of 
Rheumatology score, improved pain (by ~60%), erythrocyte sedimentation rate (by 
~11%), greater in Curcumin and Curcumin+ diclofenac vs diclofenac alone 
[289] 
Curcumin BCM-95® (curcumin, demethoxycurcumin, 
bisdemethoxycurcumin, and volatile oils from 
turmeric rhizome), 500-mg three times daily versus  
diclofenac 50-mg tablet two times daily for 28 days 
↓ Pain similar in both groups (by ~78% for both), no difference between groups 
↑ KOOS variables (n=5) similar in both groups, no difference between groups 
↑ Flatulence in diclofenac vs curcumin (by ~79%) 
↓ Requirement for H2 blockers in curcumin vs diclofenac (by 100%, i.e. zero in 
curcumin) 
↓ Incidence of adverse effects in curcumin vs diclofenac (by ~76%) 
[290] 
Curcumin Longvida®, 800 mg patented lipophilic matrix 
delivering 160 mg curcumin versus Ibuprofen (400 
mg) orally and daily for 12 weeks 
↓ Pain in both (by ~60%), no difference between groups [291] 
Curcumin Herbal formulation of curcumin (300mg), gingerols 
(7.5 mg), and piperine (3.75 mg; Mixodin) versus 
Naproxen 250 mg capsules, both twice a day for 4 
weeks 
↓ prostaglandin E2 (PGE2) in booth groups with no difference between the two 
(~27 pg/mL) 
[292] 
Curcumin Meriva tablets, a curcumin-phosphatidylcholine 
phytosome complex, 200 mg equivalent curcumin 
↓ NSAIDs use (by ~80%) vs control 
↓ Gastrointestinal complaints (by ~40%) vs control 
[293] 
daily with best available care (BCA) compared to BCA 
only as control for 8 months 
↓ Pain (by ~44%), stiffness (by ~28%), physical function (by ~40%), WOMAC score 
(by ~41%), compared to no improvements in controls 
↑ Karnofsky Performance Scale (by ~22%), compared to no improvement in 
controls 
↑ Treadmill walking distance (345% increase from baseline) compared to 89% in 
controls 
↓ inflammatory markers sCD40L (by ~56%), IL-1β (by ~35%), IL-6( by ~27%), 
sVCAM-1 (by ~30%), ESR (by ~25%), compared to no change in controls 
Curcumin Theracurmin® (10% of curcumin, 2% other 
curcuminoids such as 
demethoxycurcumin and isdemethoxycurcumin, 46% 
glycerin, 4% gum ghatti, and 38% of water; 180 mg of 
curcumin) for 8 weeks 
↓ NSAID (celecoxib) dependence (p=0.0252) 
↓ Pain (by ~55%) vs placebo 
[294] 
Curcumin C3 complex, 500 mg curcuminoid capsules including 5 
mg Bioperine, 
3 times daily for 6 weeks 
↓ Naproxen use (by ~73%) vs controls 
↓ Pain (by >38%), function (by ~41%) and WOMAC score (by ~41%) vs placebo 
 
[295] 
Ginger Topical ginger extract gel (4% gel Plygersic) versus 
sodium diclofenac gel applied 1 mL of solution 4 times 
a day for 6 weeks 
↓ Pain (by ~27%), symptoms (by ~27%) 
No difference in the above between groups 
[296] 
Ginger Diclofenac 50 mg orally or Ginger 750 or Ginger 750 
mg and Diclofenac 50 mg orally for 12 weeks 
↓ Pain and WOMAC score in all three groups, greatest improvement with Ginger 
(60%; 75%) the addition of ginger to Diclofenac (67%; 79%), compared to 
Diclofenac alone (59%; 64%) 
↓ Use of rescue medication (paracetamol) in Ginger (50%) and Ginger with 





AquaminF, 267 mg Lithothamnion, 3 capsules per 
day, 3 times a day for 12 weeks  
↑ ROM (by 5.2°) and 6MWD (By 136 ft) following 50% forced reduction from all 
NSAID in AquaminF vs placebo 
No difference in rescue medication (acetaminophen) consumption between groups 
↑ Six meter walking distance (by~92%) following 50% forced reduction from all 





Aquamin+, 2668 mg Lithothamnion, 268 mg 
seawater-derived Mg(OH)2 and pine bark extract 120 
mg versus 2000 mg Glucosamine Sulphate Daily dose 
for 12 weeks 
↓ Pain (by ~11%), symptoms (by ~7%), no change in Glucosamine 
↑ Sport and recreation (by ~9%), no change in Glucosamine 
↑ Timed up and go performance (by 7%), no change in Glucosamine 
↓ Rescue analgesic use (by 72%) vs Glucosamine 
[299] 
 
Table 1 Nutraceuticals shown to reduce analgesic and NSAID use. 
 
 
4.1 Terrestrial Botanicals 
Turmeric/curcumin extracts (spices used mainly in South Asian cooking) or 
nutraceuticals combinations where turmeric/curcumin extracts are the main active 
ingredient, have the greatest amount evidence for improving OA symptoms, with 
some recent data on NSAID and analgesics use [Table 2; 300]. Two studies have 
directly compared raw turmeric/curcumin extracts to NSAIDs and their 
effectiveness for OA symptoms [287, 288]. These data show that turmeric extracts 
either improved or were shown to be non-inferior for knee osteoarthritis (KOA) 
pain, pain during stair walking and resulted in less side effects (particularly the rate 
of abdominal pain/distention) compared to oral ibuprofen [287-289]. Furthermore, 
patented/propriety formulations of turmeric/curcumin extracts have been 
developed around the world and show some promising effects on OA (Table 2). 
Interestingly, Chandran et al demonstrated that curcumin formulated as BCM-95® 
or BCM-95®  + diclofenac sodium showed superior ‘Disease Activity Scores’, 
American College of Rheumatology score, pain, CRP levels and erythrocyte 
sedimentation rate, compared to diclofenac alone [Indian population; 289]. The 
same formulation showed similar improvements of KOOS variables, but BCM-95® 
resulted in less adverse events (including flatulence) and a lower requirements for 
H2 blockers (0% vs 28%; a group of medicines that reduce the amount of acid 
produced by the cells in the lining of the stomach), compared to diclofenac [290]. 
In the longest of these studies (8 months in a European cohort), the addition of 
Meriva® (curcuminoids 20%, phosphatidylcholine 40%, and microcrystalline 
cellulose 40%) to the “best available treatment”, reduced NSAID and analgesia use 
by 63% compared to the control group (“best available treatment” only). This 
reduction resulted in less side-effects between 45-67%, depending on the specific 
adverse advent, compared to control group [2-12%; 293]. Similarly, an alternative 
preparation (C3 complex®; Curcuminoids 500-mg capsules with 5-mg 
Bioperine®) reduced the use of naproxen by 84% (compared to 19% in placebo) in 
Iranian KOA patients and a further alternative (Theracurmin®; 10% of curcumin, 
2% other curcuminoids such as demethoxycurcumin and isdemethoxycurcumin, 
46% glycerin, 4% gum ghatti, and 38% of water; 180 mg of curcumin) reduced 
dependence on celecoxib in Japanese KOA patients [from ~70% to ~30% versus 
~80 to ~60% in placebo; 294]. Recently, Heidari‐Beni et al. [301] presented findings 
from a herbal formulation containing curcumin (300 mg), gingerols (7.5 mg) and 
piperine (3.75 mg), taken twice a day for 4 weeks. This formulation reduced PGE2 
(see above text and Figure 1) of KOA patients to the same extent as Naproxen (250 
mg capsules daily). There is significant mechanistic evidence to support these in 
vivo therapeutic effects. Turmeric/curcumin extracts have been shown to reduce 
proinflammatory cytokines such as tumour necrosis factor alpha, interleukin (IL)-1 
beta, IL-8, IL-6 and structural degradation protases such as matrix 
metalloproteinases, collagenase, induce positive cell behavioural characteristics 
(induces apoptosis and growth arrest) and anti-oxidative properties (through 
stimulation of nuclear factor-erythroid-2-related factor 2 (Nrf2) [292, 302-311]. Of 
particular interest to the present chapter, turmeric/curcumin extracts inhibit the 
NFkB pathway and other proinflammatory signalling pathways including COX-2, 
AP-1, Egr-1, STAT (signal transducers and activators of transcription) and mitogen-
activated protein (MAP) kinases [309, 310, 312]. Considering these molecular 
targets, turmeric/curcumin extracts appear to enact there in vivo effects via similar 
mechanisms of action as commonly used pharmaceutical agents (Figure 1). These 
data clearly point to the positive impact that turmeric/curcumin extracts, including 
propriety formulations, can have on NSAID and analgesia use in the short term (best 
effects from study durations generally ≤12 weeks). While the long-term benefits are 
still being investigated the current data suggests that turmeric/curcumin extracts 
could be recommended as an early stage treatment adjunct. 
 
Alternative terrestrial botanicals have shown some advantages for OA. Three studies 
have investigated avocado/soybean extracts and their potential in reducing NSAID 
and analgesics use. One large randomised control trial (n=260) showed that after 
30 days (and continued to day 90) of supplementation, the extracts (300 or 600mg) 
reduced the daily intake of NSAID and analgesics compared to placebo. 
Furthermore, 71% (compared to 36% in placebo) of avocado/soybean extract 
participants reduced their daily intake by greater than 50%, [281]. Although it must 
be noted that the treatment was stopped in nine participants due to adverse events 
from the extract, however the authors did not statistically analyse incidence of 
adverse events of the remaining participants, but they were generally similar to 
placebo. These results were somewhat supported by a smaller (n=31; part of a large 
cohort receiving a number of nutraceutical compounds) observational study 
showing that the proportion of OA patients using analgesics and NSAIDs dropped 
by 34% over 6 months consuming avocado/soybean extracts [282]. Although, in this 
large scale “real-world” (PEGASus) study cohort where analgesic and NSAID use 
was assessed by phone interview bi-monthly over 2 years, avocado/soybean extracts 
showed no effect on reducing medication use [313]. Recently, a 2-month 
supplementation of avocado/soybean unsaponifiables (n=30; 300 mg daily) was 
compared to celecoxib (n=30; 200 mg/day) for changes in a biomarker of cartilage 
breakdown (Cartilage oligomeric matrix protein; COMP). The results showed that 
both interventions reduced serum COMP levels with a tendency for greater 
improvements with avocado/soybean unsaponifiables [33.8% vs. 30.3%; p=0.06; 
283]. These data in addition to other mechanistic work show that avocado/soybean 
unsaponifiables can affect both inflammatory and structural protein biomarkers of 
OA pathology. Specifically they can inhibit IL-1, reduce production of stromelysin, 
IL-6, IL-8 and PGE-2, increase the expression of TGF-β and activate collagen 
synthesis [283, 314-316]. There is some debate over the efficacy of avocado/soybean 
extracts to alleviate analgesics and NSAID use but there is developing molecular 
evidence that they may elicit similar reductions on in vivo cartilage breakdown 
which requires further investigation. 
 
Two studies investigated Ginger root extract formulations in OA NSAID use. 
Compared to 1% diclofenac gel, topical ginger extract (Plygersic gel) reduce KOOS 
variables (pain symptoms etc.) equally after a six week intervention in mild 
radiographic KOA [296]. Further, oral consumption of a Ginger root extract 
formulation, compared 1) 50 mg of oral Diclofenac with Ginger 750, 2) Ginger 750 
mg and 3) Diclofenac 50 mg for 12 weeks [297]. All interventions decreased pain 
and WOMAC variables but there was a reduction in rescue medication in the ginger 
groups, although this was not statically significant [297]. While these results are 
interesting, significantly more research is needed with larger more well controlled 
studies but there is molecular evidence to support these reported effects. Ginger root 
species has can block the formation of inflammatory mediators such as 
thromboxane, leukotrienes and prostaglandins and inhibit COX and lipoxygenase 
in arachidonic acid metabolism [317-325] i.e. similar mechanisms to those 
presented in Figure 1. 
 
Finally, the trade marked Pycnogenol® (pine bark extract; 100mg) has been shown 
to reduces NSAID use by 58%, compared to only 1% in the placebo group in early-
KOA patients over a 12 week [286]. This resulted in reduced hospital admissions 
and days spent in hospital by 50% compared to placebo[n=156; 286]. As with the 
above, Pycnogenol inhibits activation of NFκB pathway mediators, particularly, 
COX and pain-producing prostaglandins and also active metabolomic compounds 
with anti-inflammatory bio-efficacy [326-328]. Again, these data are interesting and 
demonstrate good potential but require further in vivo replication in relation to 
NSAID and analgesic. 
 
4.2 Marine Fauna 
New Zealand Green Lipped Mussel ( Perna canaliculus) lipid extracts have recently 
been investigated for their potentially benefits for OA symptoms. Moderate-to-
severe hip and knee OA patients received 600 mg of Biolex®-GLM for 12 weeks or 
a placebo and were allowed to consume paracetamol for additional pain relief [285]. 
Participants consuming the placebo took more paracetamol each week of the 12 
weeks resulting in a statically significant change at the final week (p=0.001), 
however did not differ in NSAID equivalence score. This suggests that there may be 
some potential for Green Lipped Mussel to reduce analgesic medication, although 
less so than others mentioned herein. Again, Green Lipped Mussel appears to 
inhibit COX enzymes, competitive inhibition of arachidonic acid metabolism and 
reduce chronic inflammation [329]. 
 
A fish oil and Urtica dioica preparation has also been shown to reduce medication 
use in OA. A proprietary combination of omega-3 and omega-6 fatty acids, Urtica 
dioica (the common nettle), zinc and vitamin E (Phytalgic®) progressively reduced 
NSAID and analgesia use over a tree month period [n=81; 6.5 Paracetamol 500 mg-
Equivalent per week, compared to 16.5 in the placebo group; 284]. The authors 
ascribed this adaptation to the anti-inflammatory potential of the mineral 
composition, mainly from Urtica dioica within the formulation rather than the fish 
oil component [284]. This was most likely the case as a previous study showed no 
effect of cod liver oil an OA [330] and articles referenced to show a mechanistic 
potential for fish oil components (n-3 and n-6 polyunsaturated fatty acids) have 
recently been retracted [331, 332]. 
 
4.3 Marine Botanicals 
The marine red Algae species Lithothamnion corallioide, rich in sea water derived 
minerals including Calcium and Magnesium (AquaminF®), have recently been 
investigated for a potential impact on NSAID usage. In a randomised control trial of 
moderate-to-severe KOA patients that were regularly consuming NSAIDs, 
AquaminF (534 mg daily) was an effective agent for improving physical 
performance (six minuet walking distance), when NSAID use was intentionally 
reduced to 50% of previous consumption, but not when NSAID consumption was 
reduced to zero [298]. Furthermore, Lithothamnion (2668 mg) combined with 
seawater-derived Mg(OH)2 (268 mg) and pine bark extract (120 mg) reduced 
analgesic and NSAID use by 72% compared to Glucosamine Sulphate (2000 mg 
Daily dose)[299]. Mechanistically, Lithothamnion corallioide species appear to 
have the ability to inhibit the NFκB pathway, reduce inflammatory cytokines such 
as tumour necrosis factor alpha (TNF-α), interleukin 1 beta (IL-1β) and COX2, along 
with reduced serum TNF-α [333-336]. This suggested there is potential for 
Lithothamnion species to reduce the KOA-related drug dependency in vivo with 
mechanistic rationale similar to that of pharmaceuticals (Figure 1). It appears as 
though Lithothamnion species have the ability to improve physical function and 
analgesia with reduced NSAID use with reduce further reduction in drug use when 
combined with other nutraceuticals previously shown to reduce NSAID use. With 
larger scale replication and confirmation, Lithothamnion species could develop into 
a recommended early stage treatment adjunct. 
 
5 Discussion and conclusions 
These data are of considerable interest to those suffering from OA and medical 
practitioners concerned with the broader health impacts of pharmaceuticals use in 
OA patients. There appears to be a growing body of evidence suggesting that a 
variety of nutraceutical compounds, many in preparatory formulations, could 
provide some relief from the burden of NSAID and analgesic dependence, thus their 
associated short-term side-effects. However, currently the data is limited with 
respect to replication, sample size and duration, making conclusions about long 
term effectiveness difficult. The one potential exception is turmeric/curcumin 
extracts that in a recent meta-analysis was shown that typically 1000 mg/day of 
curcumin to be effective for improve OA symptoms (potentially better that NSAID) 
over 8-12 weeks - but the authors still call for significantly more research, 
specifically with increased sample size and better design quality [300]. 
 
While the precise molecular mechanisms of OA progression remain unclear, it 
appears to be exacerbated by the activation of NFκB signalling pathway, initiated by 
a host of mechanical and chemical stress stimuli, including excessive mechanical 
stress brought about by surplus body mass, proinflammatory cytokines and 
extracellular matrix degradation products [337, 338]. These actions reduce the 
amount of articular cartilage in the joints and degrade subchondral bone, thus 
induce pain and difficulty in movements. As a result, OA treatments focus on 
relieving pain and swelling, improving joint mobility, increasing musculoskeletal 
strength and minimizing the disabling effects of the disease [339]. The NFκB 
signalling pathway and inflammatory mechanisms appear to be the molecular 
actions of the majority of the above nutraceuticals in combination with the 
inhibition of COX enzymes. These imply that their mechanism of action for pain 
relief (and therefore potential reduction in analgesic use) are via peripheral 
nociceptive action with little interaction through neuropathic mechanisms (unless 
through local inflammatory assault of nerve fibres). 
 
As discussed throughout, there appears to be even further benefit through the 
combinations of nutraceuticals that may have an additive effects to reduce 
NSAID/analgesic use and are recommended [263]. However, additional work needs 
to be carried out to understand the individual effects of these combinations in 
addition to the synergistic impact. This requirement is evident through the work by 
Jacquet et al. [284] where it appears that the proposed benefit of the combination 
was not attributable to the ingredient that is mentioned and discussed firstly (fish 
oil), rather the benefit lies with Urtica dioica and mineral composition. These 
combinations are often proprietary formulations where the precise combination will 
not be shared. However, where this is not the case this can be achieved through in 
vitro experimentation to elucidate the mechanisms of action both individually and 
combined. 
 
In conclusion, this chapter has described and discussed chronic pain, specifically 
osteoarthritis, and presented evidence that specific nutraceuticals and 
combinations have potential to either elicit the same pain reliving effect of NSAIDs 
and analgesics or reduce the dependency on these drugs. Specifically, the greatest 
evidence exists for the inclusion of turmeric/curcumin extracts as an mild-OA 
treatment adjunct to reduce NSAID consumption. Any reduction in the use of 
harmful pharmaceutical drugs should be a welcome inclusion to any treatment plan 
with some nutraceuticals, that appear to interact with similar molecular pathways 
as the discussed analgesics, may be capable of offering such benefit. However, it 
must be noted that significantly more experimental evidence is required for a 
number of these formulations before specific recommendations can be made. 
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